Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study

Cancer

Volumn 121, Issue 22, 2015, Pages 4053-4061

  Brinkman, Tara M ^a   Bass, Johnnie K ^a   Li, Zhenghong ^a   Ness, Kirsten K ^a   Gajjar, Amar ^a   Pappo, Alberto S ^a   Armstrong, Gregory T ^a   Merchant, Thomas E ^a   Srivastava, Deo Kumar ^a   Robison, Leslie L ^a   Hudson, Melissa M ^a   Gurney, James G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

Author keywords

central nervous system solid tumors; childhood cancer; hearing loss; non central nervous system solid tumors; social outcomes

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; EDUCATIONAL STATUS; EMPLOYMENT; EPENDYMOMA; FEMALE; GERM CELL TUMOR; HEARING AID; HEARING IMPAIRMENT; HUMAN; INDEPENDENT LIVING; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDULLOBLASTOMA; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; OSTEOSARCOMA; OTOTOXICITY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RISK FACTOR; SOCIAL ASPECT; ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; COMPLICATION; HEARING LOSS; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; SURVIVOR;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; SURVIVORS;

EID: 84946492601     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29604     Document Type: Article

References (36)

1. Howlader N, Noone AM, Krapcho M, et al., Surveillance, Epidemiology, and End Results Program. Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014.
2. Hudson MM, Ness KK, Gurney JG, et al., Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309: 2371-2381.
3. Robison LL, Hudson MM,. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2014; 14: 61-70.
4. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P,. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010; 125: e938-e950.
5. Knight KR, Kraemer DF, Neuwelt EA,. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005; 23: 8588-8596.
6. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J,. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991; 19: 295-300.
7. Li Y, Womer RB, Silber JH,. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40: 2445-2451.
8. Einar-Jon E, Trausti O, Asgeir H, et al., Hearing impairment after platinum-based chemotherapy in childhood. Pediatr Blood Cancer. 2011; 56: 631-637.
9. Landier W, Knight K, Wong FL, et al., Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales - A report from the Children's Oncology Group. J Clin Oncol. 2014; 32: 527-534.
10. Brock PR, Knight KR, Freyer DR, et al., Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012; 30: 2408-2417.
11. Wright CG, Schaefer SD,. Inner ear histopathology in patients treated with cis-platinum. Laryngoscope. 1982; 92: 1408-1413.
12. Meech RP, Campbell KC, Hughes LP, Rybak LP,. A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear Res. 1998; 124: 44-59.
13. Comis SD, Rhys-Evans PH, Osborne MP, Pickles JO, Jeffries DJ, Pearse HA,. Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. J Laryngol Otol. 1986; 100: 1375-1383.
14. Hinojosa R, Riggs LC, Strauss M, Matz GJ,. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol. 1995; 16: 731-740.
15. Schweitzer V, Hawkins JE, Lilly DJ, et al., Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg. 1984; 92: 38-49.
16. Bertolini P, Lassalle M, Mercier G, et al., Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004; 26: 649-655.
17. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al., Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009; 52: 637-643.
18. Hua C, Bass JK, Khan R, Kun LE, Merchant TE,. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys. 2008; 72: 892-899.
19. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML,; Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics. 2007; 120: e1229-e1236.
20. Karpa MJ, Gopinath B, Beath K, et al., Associations between hearing impairment and mortality risk in older persons: the Blue Mountains Hearing Study. Ann Epidemiol. 2010; 20: 452-459.
21. Gopinath B, Schneider J, McMahon CM, Teber E, Leeder SR, Mitchell P,. Severity of age-related hearing loss is associated with impaired activities of daily living. Age Ageing. 2012; 41: 195-200.
22. Gopinath B, Wang JJ, Schneider J, et al., Depressive symptoms in older adults with hearing impairments: the Blue Mountains Study. J Am Geriatr Soc. 2009; 57: 1306-1308.
23. Hudson MM, Ness KK, Nolan VG, et al., Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study. Pediatr Blood Cancer. 2011; 56: 825-836.
24. Ojha RP, Oancea SC, Ness KK, et al., Assessment of potential bias from non-participation in a dynamic clinical cohort of long-term childhood cancer survivors: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2013; 60: 856-864.
25. Landier W, Bhatia S, Eshelman DA, et al., Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004; 22: 4979-4990.
26. Chang KW, Chinosornvatana N,. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010; 28: 1788-1795.
27. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR,. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002; 94: 39-49.
28. Alfano CM, McGregor BA, Kuniyuki A, et al., Psychometric evaluation of the Brief Cancer Impact Assessment among breast cancer survivors. Oncology. 2006; 70: 190-202.
29. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
30. Wechsler D,. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Harcourt Assessment; 1999.
31. Whelan K, Stratton K, Kawashima T, et al., Auditory complications in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011; 57: 126-134.
32. Kirchhoff AC, Leisenring W, Krull KR, et al., Unemployment among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Med Care. 2010; 48: 1015-1025.
33. Gurney JG, Krull KR, Kadan-Lottick N, et al., Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27: 2390-2395.
34. Meister H, Walger M, Brehmer D, von Wedel UC, von Wedel H,. The relationship between pre-fitting expectations and willingness to use hearing aids. Int J Audiol. 2008; 47: 153-159.
35. McCormack A, Fortnum H,. Why do people fitted with hearing aids not wear them? Int J Audiol. 2013; 52: 360-368.
36. Gurney JG, Bass JK, Onar-Thomas A, et al., Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014; 16: 848-855.